Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
 
Researchers:
Have you heard a story, statistic, or discovery that might interest the public? Let us know about it!
 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

  

Alzheimer's Disease Research - Current Award

Photo Pending

Michael Wolfe, Ph.D.

Brigham and Women's Hospital
Boston, MA

Title: Gamma-Secretase Modulators for Alzheimer's Disease
Non-Technical Title: Selective Amyloid-Lowering Agents for Alzheimer's Disease

Co-Investigator(s):
Corinne Augelli-Szafran, Brigham and Women's Hospital

Duration: April 1, 2010 - March 31, 2013
Award Type: Standard
Award Amount: $400,000


Summary:

All of the specific aims in this research address one main goal: to identify gamma-secretase modulating drugs that are efficacious in a standard Alzheimer’s disease transgenic animal model and suitable for pre-clinical drug development. The ultimate goal is to identify a drug candidate for the treatment of Alzheimer's disease.

Details:

The goal of this project is to identify new agents that lower brain levels of amyloid, a protein widely thought to initiate Alzheimer's disease. We seek to accomplish this by selectively affecting an amyloid-producing enzyme so that this enzyme can continue serving a critical role it plays in normal human health. We have identified small, drug-like molecules that affect the enzyme in this way and now seek to advance them by (1) making variations of these molecules to optimize their selective effects on the amyloid-producing enzyme; (2) evaluating promising molecules for other properties that would suggest they might last long enough in the body be able to get where they need to be; (3) testing drug candidates in animal models for Alzheimer's disease; and (4) working toward the identification of backup drug candidates.